Information Provided By:
Fly News Breaks for January 4, 2018
FATE
Jan 4, 2018 | 06:50 EDT
Piper Jaffray analyst Edward Tenthoff names Fate Therapeutics a top pick for 2018 with an Overweight rating and $10 price target. The analyst is positive on the FATE-NK100 data and investigational new drug filings on the first-ever iPSC-derived cell therapies.